Maxitrol® Ointment
neomycin 0.35%, polymyxin B, dexamethasone 0.1% · ophthalmic ointment
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation where bacterial infection or a risk of infection exists
About a 0.5 inch ribbon into the conjunctival sac up to 3 or 4 times daily; not more than 8 g before re-examination
Contraindications
- Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva.
- Mycobacterial infection of the eye.
- Fungal disease of ocular structures.
- Known or suspected hypersensitivity to a component, with hypersensitivity to the antibiotic component occurring at a higher rate than to the other components.
Neomycin 3.5 mg/g, polymyxin B sulfate 10,000 units/g, dexamethasone 0.1% ointment, 3.5 g aluminum tube.
Corticosteroid plus two antibacterials: dexamethasone suppresses the inflammatory response and probably delays or slows healing, neomycin blocks bacterial protein synthesis, and polymyxin B permeabilizes the gram-negative outer membrane. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.
Warnings & Precautions
- Cutaneous sensitization: Products containing neomycin sulfate may cause cutaneous sensitization, and sensitivity to topically administered aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions; discontinue if hypersensitivity develops.
- Cross-hypersensitivity: Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.
- Periocular contact allergy: In two German cohorts of patients with periorbital dermatitis, allergic contact dermatitis was the main cause (44.3% and 31.6%), and neomycin sulfate (8%) was among the most relevant allergens.
- Glaucoma and cataract: Prolonged use may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
- Secondary ocular infections: Prolonged use may suppress the host response and increase the hazard of secondary ocular infections; consider persistent fungal corneal infection after prolonged steroid dosing, and suspect fungal infection in any persistent corneal ulceration.
- Infection masking: In acute purulent conditions or parasitic infections of the eye, steroids may mask infection or enhance existing infection.
- Viral eye infections: Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye, including herpes simplex. Employment of steroid medication in the treatment of herpes simplex requires great caution, and frequent slit lamp microscopy is recommended.
- Corneal or scleral thinning: Perforation has occurred with topical steroids in diseases that thin these tissues.
- Intraocular pressure: If this product is used for 10 days or longer, IOP should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma, and IOP should be checked frequently.
- Delayed healing and bleb formation: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
- Not for injection: This ointment is not for injection.
- Does not provide adequate coverage: This product does not provide adequate coverage against Serratia marcescens and Streptococci, including Streptococcus pneumoniae.
- Persistent or aggravated inflammation or pain: If inflammation or pain persists longer than 48 hours or becomes aggravated, discontinue use and consult a physician.
- Temporarily blurred vision: Vision may be temporarily blurred following dosing, so care should be exercised in operating machinery or driving a motor vehicle.
- Initial prescription and renewal: The initial prescription and renewal beyond 8 g should be made only after examination with magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.
Common Side Effects
- Hypersensitivity: Allergic sensitization is the reaction reported most often from the anti-infective components; exact incidence figures are not available.
- Ocular, corticosteroid: IOP elevation with possible glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.
- Ocular, secondary infection: Fungal keratitis is particularly prone to develop with long-term steroid application and secondary bacterial infection follows suppression of host response; keratitis, conjunctivitis, corneal ulcer, and conjunctival hyperemia have occasionally been reported with steroid use.
- Ocular, postmarketing: Ulcerative keratitis.
- Systemic: Headache and Stevens-Johnson syndrome identified in postmarketing use.
Pregnancy: Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose. In the mouse, corticosteroids produce fetal resorptions and cleft palate; in the rabbit, they have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, and palate. There are no adequate or well-controlled studies in pregnant women, and prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation. Use during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects; whether topical ocular dosing yields detectable milk levels is unknown, so use with caution.
Safety and effectiveness in pediatric patients not established; this label sets no age threshold.